The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2023 | Updates from the LINKER-MM1 study: linvoseltamab in R/R multiple myeloma
Joshua Richter, MD, Mount Sinai Medical Center, New York City, NY, discusses updates from the Phase I/II LINKER-MM1 study (NCT03761108), which is evaluating two different doses of linvoseltamab in patients with relapsed/refractory (R/R) multiple myeloma. Dr Richter comments on the safety and toxicity profile of this agent, including rates of cytokine release syndrome (CRS) observed. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultant/advisor: Janssen, BMS, Pfizer, Karyopharm, Sanofi, Takeda, Abbvie, Genentech
Speakers bureau: Janssen, BMS, Sanofi, Adaptive Biotechnologies
